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Introduction
Osteoarthritis (OA) and rheumatoid arthritis (RA) are debilitating joint diseases, and although they have a different aetiology a key pathological feature of both is the loss of articular cartilage 1 . Cannabis-based medicine Sativex has been shown to have analgesic effects and to suppress disease activity in patients with RA 2 .
Cannabinoids also have anti-inflammatory effects and reduce joint damage in animal models of arthritis 3e5 . In vitro studies have
shown that cannabinoids reduce cytokine production from RA fibroblasts and the release of matrix metalloproteinases (MMPs) from fibroblast-like synovial cells 6e8 . Cannabinoids also have direct effects on cartilage extracellular matrix (ECM) breakdown; reducing interleukin 1 (IL-1) induced proteoglycan and collagen degradation in bovine cartilage 9 . There is thus increasing evidence to suggest that cannabinoids have chondroprotective effects and may be of value in the treatment of arthritis 10 .
During OA and RA there is a shift in the equilibrium between catabolic and anabolic activities 1 . As a result the breakdown of collagen and proteoglycans may exceed the rate of synthesis of new matrix molecules resulting in cartilage degradation. Another contributing factor in cartilage breakdown in OA and RA is an increase in inflammatory cytokines particularly IL-1 and tumour necrosis factor (TNF) produced by the articular chondrocytes or cells of the synovium 11 . This results in an increase in MMPs particularly MMP-3 and MMP-13, which are expressed in RA and OA cartilage and synovial tissue 12e20 , which is not accompanied by an increase in their tissue inhibitors of matrix metalloproteinases (TIMPs) 21, 22 resulting in a net increase in MMPs. MMP inhibition has been proposed as a possible mechanism to prevent breakdown of cartilage tissue in arthritis, provided the necessary functional specificity can be achieved 23 .
To investigate further the potential of cannabinoids to regulate cartilage breakdown we have studied the effects of synthetic cannabinoid WIN-55,212-2 mesylate (WIN-55) on basal and IL-1b stimulated MMP-3, -13, TIMP-1 and -2 expression in human articular chondrocytes from human OA cartilage tissue in monolayer and 3D alginate bead culture. WIN-55 is an agonist at the classical cannabinoid receptors, cannabinoid receptor 1 and 2 (CB1 and 2), but also has been shown to activate other receptors including peroxisome proliferator activated receptors alpha and gamma (PPARa and g) 24e26 .
Thus the expression of these receptors in cultured OA chondrocytes was determined to identify potential targets of WIN-55.
Materials and methods

Human cartilage tissue
Human chondrocytes were obtained from articular cartilage (n ¼ 9) removed from patients with symptomatic OA at the time of total knee replacement (Supplementary Table I ). Cartilage was obtained under the National Research Ethics Service approval held by the Sheffield Musculoskeletal Biobank. All patients provided written, informed consent prior to participation. Cartilage blocks were taken from each anatomic compartment within the knee (n ¼ 6e7) (medial and lateral tibio-femoral and patello-femoral compartments). Cartilage tissue was graded macroscopically 0e4 using the Outerbridge classification 27 . Chondrocytes were isolated from grade 0 (n ¼ 3), grade 2 (n ¼ 6) and grade 3 (n ¼ 5) cartilage tissue as representative of non-degenerate, low degenerate and intermediate degenerate cartilage tissue. Cartilage from grade 4 severe degenerate tissue was not used in the study as the cell yield obtained was not sufficient.
Isolation of human chondrocytes
Cartilage tissue was digested in 0.25% trypsin (SigmaeAldrich, Poole, UK) at 37 C for 30 min followed by digestion in 3 mg/ml collagenase type I (SigmaeAldrich, Poole UK) in Dulbecco's modified Eagle's medium (DMEM)/F-12 (1:1) (Gibco, Paisley, UK) supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Gibco, Paisley, UK), 2 mM glutamine (Gibco, Paisley, UK), 100 U/ml penicillin, 100 mg/ml streptomycin (Gibco, Paisley, UK), 2.5 mg/ml amphotericin B (SigmaeAldrich, Poole, UK), and 50 mg/ml ascorbic acid (SigmaeAldrich, Poole, UK) (complete media), at 37 C for 16 h.
Cells were passed through a 70 mm cell strainer and washed twice in DMEM/F12 supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml, streptomycin, 2.5 mg/ml amphotericin B and 50 mg/ml ascorbic acid (serum free media). Cells were counted and the viability checked using trypan blue staining. Chondrocytes were cultured in monolayer in complete media in a humidified atmosphere of 5% CO 2 at 37 C and harvested at passage 2.
Monolayer culture
Chondrocytes harvested at passage 2 were seeded at a cell density of 1 Â 10 6 cells/well in a six well plate and maintained in complete media in a humidified atmosphere of 5% CO 2 at 37 C for 24 h prior to treatment to allow cells to adhere to the cell culture plate.
Alginate bead culture
When cultured in monolayer, chondrocytes dedifferentiate into fibroblast like cells 28e30 , therefore alginate beads were used to redifferentiate the chondrocytes to their native phenotype. Chondrocytes harvested at passage 2 were encapsulated in alginate beads at a cell density of 2 Â 10 6 cells/ml, as previously described 31 . Alginate beads were cultured in complete media in a humidified atmosphere of 5% CO 2 at 37 C and the media changed every other day. Chondrocytes were redifferentiated in alginate beads for 4 weeks prior to treatment.
Cytotoxicity studies
The 
MMP-3 and -13 Enzyme Linked Immunosorbent Assays (ELISAs)
ELISAs (R&D Systems, Abingdon, UK) were used according to the manufacturer's instructions to measure pro and active MMP-3 protein expression (ng/ml) and pro MMP-13 protein expression (pg/ml) in alginate bead conditioned culture media following treatment with 10 mM WIN-55 with and without 10 ng/ml IL-1b stimulation for 48 h.
RNA extraction from monolayers
For each of the three patient samples obtained from Outerbridge grade 0, 2 and 3 (n ¼ 9), patient samples were tested in triplicate. Following treatments, media was removed, cells washed in 1xPBS and RNA extracted in 1 ml of TRIzol reagent (Invitrogen, Paisley, UK) following the manufacturer's instructions. RNA was resuspended in 14 ml sterile deionised water.
RNA extraction from alginate beads
For each of the three patient samples obtained from Outerbridge grade 0, 2 and 3 (n ¼ 9), patient samples were tested in triplicate. RNA was extracted from alginate beads using two beads per extraction as described previously 31 . The resulting RNA was then resuspended in 100 ml of sterile deionised water and the RNA was purified using RNeasy clean up columns (Qiagen, Crawley, UK) according to the manufacturer's instructions and RNA eluted in 14 ml of sterile deionised water.
Reverse transcription-real-time polymerase chain reaction (qRT-PCR) cDNA was formed as described previously 31 . Real-time PCR was used to investigate MMP-3, -13, TIMP-1, and -2 gene expression using Applied Biosystems Taqman Gene Expression Assays (Table I) . The reactions were performed for 40 cycles using Taqman Fast Universal PCR Master Mix (Applied Biosystems, Paisley, UK) on an ABI StepOnePlus real-time PCR machine (Applied Biosystems, Paisley, UK). The data were collected and the fold changes in gene expression analysed using the 2 ÀDDCt method 32 . Gene expression was normalised to housekeeping genes GAPDH and 18S together with untreated controls.
Cannabinoid receptor expression in OA chondrocytes
Chondrocytes isolated from four patient samples of grade 2e3 cartilage at passage 2 were plated at a density of 1 Â 10 5 cells in eight well chamber slides and allowed to adhere overnight. Chondrocytes were fixed in 4% formalin and endogenous peroxidases were quenched. Following 0.01% chymotrypsin antigen retrieval at 37 C for 20 min cells were blocked in 25% v/v goat serum/BSA. Cells were incubated with rabbit polyclonal antibodies (Abcam) overnight at 4 C against CB1 (1/100), CB2 (1/50), PPARa (1/150) and PPARg (1/50). A rabbit isotype IgG antibody (Abcam) was used as negative control. Following washing cells were incubated with biotinylated goat anti-rabbit secondary antibody (1/ 300: Abcam) and binding detected using streptavidinebiotinylated horseradish peroxide complex (Vector Laboratories, Peterborough, UK) with 3,3 0 -diaminobenzidine tetrahydrochloride substrate (SigmaeAldrich). Cells were counterstained using Mayer's Haematoxylin (Leica Microsystems, Milton Keynes, UK) dehydrated, cleared and mounted in Pertex (Leica Microsystems). Immunopositivity was visualised and images captured using an Olympus BX60 microscope and QCapture Pro v8.0 software (MediaCybernetics, Marlow, UK).
Statistical analysis
Data was shown to be non-parametric via a ShapiroeWilk test hence statistical significance between DMSO vehicle control and treatment groups was determined using the non-parametric Kruskall-Wallis multiple comparisons test and Conover-Inman post hoc test; P < 0.05 was considered statistically significant for real-time PCR and ELISA analysis. All statistical analysis was performed using StatsDirect. All data analysis was performed using individual replicates for each treatment group.
Results
Cytotoxicity studies
Cytotoxicity studies showed that WIN-55 was not toxic to chondrocytes at the concentrations used (Data not shown). Supplementary Fig. 2(AeD) ]. WIN-55 was used at 10 mM in all following treatments, as this was the maximal inhibitory nontoxic concentration.
Effects of DMSO in monolayer and alginate bead culture
No differences in gene or protein expression were observed between untreated cells compared to cells treated with 0.1% DMSO and 10 ng/ml IL-1b treatment in combination with 0.1% DMSO compared to IL-1b treatment alone (Data not shown). Therefore 10 ng/ml IL-1b in combination with 0.1% DMSO and 0.1% DMSO controls were used for all real-time PCR and ELISA analysis.
Effect of WIN-55 on IL-1b induced MMP-3 and MMP-13 gene expression in monolayer
In order to determine the effects of WIN-55 on MMPs in the presence of the inflammatory cytokine IL-1b, real-time PCR was used to measure the gene expression of MMP-3 and -13 in chondrocytes obtained from macroscopically graded OA cartilage. For this purpose chondrocytes were stimulated with IL-1b to induce MMP expression and co-treated with WIN-55. The effects of WIN-55 alone were also investigated. IL-1b stimulation significantly induced MMP-3 gene expression in chondrocytes isolated from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage and MMP-13 in chondrocytes isolated from grade 0 (P < 0.0001), grade 2 (P ¼ 0.02) and grade 3 cartilage (P < 0.0001) compared to DMSO vehicle control [ Fig. 1(AeF) ]. Treatment with WIN-55 in combination with IL-1b significantly reduced MMP-3 and -13 gene expression in chondrocytes derived from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage compared to IL-1b stimulation alone [ Fig. 1(AeF) ]. WIN-55 treatment in combination with IL-1b also significantly reduced MMP-3 gene expression in chondrocytes isolated from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage and MMP-13 gene expression in chondrocytes isolated from grade 0 (P < 0.0001), grade 2 (P ¼ 0.01) and grade 3 (P < 0.0001) compared to DMSO vehicle control [ Fig. 1(AeF) ]. WIN-55 treatment alone significantly reduced MMP-3 gene expression in grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage derived chondrocytes below basal levels compared to DMSO vehicle control [ Fig. 1(AeC) ]. WIN-55 treatment alone also significantly decreased MMP-13 gene expression in grade 0 (P ¼ 0.002) and 3 (P < 0.0001) cartilage derived chondrocytes compared to DMSO control [Figs. 1(D) and 1(F)]. MMP-13 was only expressed in two samples in chondrocytes isolated from grade 2 cartilage following WIN-55 treatment therefore statistical analysis could not be performed [ Fig. 1(E) ]. chondrocytes from grade 2 (P ¼ 0.11) cartilage and both MMP-3 (P ¼ 0.58) and -13 (P ¼ 0.11) gene expression in chondrocytes from grade 3 cartilage compared to DMSO vehicle control; however this was not significant [ Fig. 2 Fig. 2(B) ]. MMP-13 was abolished in chondrocytes from grade 2 and 3 cartilage treated with WIN-55 alone [ Fig. 2(D-F) ].
Effects of WIN-55 on IL-1b induced TIMP-1 and TIMP-2 gene expression in monolayer
In order to determine the effects of WIN-55 on the inhibitors of MMP-3 and -13 the gene expression of TIMP-1 and -2 was investigated following WIN-55 treatment both alone and in combination with IL-1b. IL-1b stimulation had no significant effect on TIMP-1 gene expression in chondrocytes derived from grade 0 (P ¼ 0.75), 2 (P ¼ 0.60) and 3 (P ¼ 0.12) cartilage or TIMP-2 gene expression in chondrocytes isolated from grade 0 (P ¼ 0.77), 2 (P ¼ 0.49) and 3 (P ¼ 0.98) cartilage [ Fig. 3(AeF) ]. However, WIN-55 treatment in combination with IL-1b resulted in a significant decrease in TIMP-1 gene expression compared to DMSO vehicle control and IL-1b stimulated chondrocytes derived from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P ¼ 0.001) cartilage [ Fig. 3(AeC) ]. WIN-55 alone also significantly reduced TIMP-1 gene expression in chondrocytes derived from grade 0 (P < 0.0001) and 2 (P < 0.0001) cartilage below basal levels [ Fig. 3(A) and (B) ]. TIMP-1 gene expression was decreased in chondrocytes derived from grade 3 cartilage following WIN-55 treatment however this was not significant (P ¼ 0.11) [ Fig. 3(C) ]. TIMP-2 gene expression was significantly reduced following WIN-55 treatment in combination with IL-1b compared to DMSO vehicle control and IL-1b stimulation in chondrocytes derived from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage [ Fig. 3(DeF) ]. WIN-55 alone significantly reduced the gene expression of TIMP-2 below basal levels in chondrocytes isolated from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage [ Fig. 3(DeF) ].
Effects of WIN-55 on IL-1b induced TIMP-1 and TIMP-2 gene expression on chondrocytes cultured in alginate beads
TIMP-1 gene expression was significantly increased in grade 2 (P < 0.0009) and 3 cartilage derived chondrocytes (P ¼ 0.02) following IL-1b stimulation [ Fig. 4 (B) and (C)] but not in grade 0 (P ¼ 0.24) cartilage chondrocytes compared to DMSO vehicle control [ Fig. 4(A) ]. In contrast TIMP-2 gene expression was significantly decreased following IL-1b treatment in chondrocytes extracted from grade 0 (P ¼ 0.009), 2 (P ¼ 0.001) and 3 (P < 0.0001) cartilage compared to DMSO vehicle control [ Fig. 4(DeF) ]. WIN-55 treatment in combination with IL-1b resulted in a significant decrease in TIMP-1 gene expression in chondrocytes derived from grades 0 (P < 0.0001), 2 (P < 0.0001), and 3 (P < 0.0001), cartilage and TIMP-2 gene expression in chondrocytes isolated from grades 0 (P < 0.0001), 2 (P < 0.0001), and 3 (P ¼ 0.0007), cartilage compared to IL-1b stimulation [ Fig. 4(AeF) ]. WIN-55 treatment in combination with IL-1b also resulted in a significant decrease in TIMP-1 gene expression in chondrocytes derived from grades 0 (P < 0.0001), 2 (P < 0.0001), and 3 (P < 0.0001), cartilage and TIMP-2 gene expression in chondrocytes isolated from grades 0 (P < 0.0001), 2 (P < 0.0001), and 3 (P < 0.0001) cartilage compared to DMSO control [ Fig. 4(AeF) ]. WIN-55 treatment alone significantly reduced both TIMP-1 gene expression in chondrocytes derived from grade 0 (P ¼ 0.0005), 2 (P < 0.0001) and 3 (P ¼ 0.0003) cartilage below basal levels [ Fig. 4(AeC) ]. WIN-55 treatment alone significantly reduced both TIMP-2 gene expression in chondrocytes derived from grade 0 (P < 0.0001), 2 (P < 0.0001) and 3 (P < 0.0001) cartilage below basal levels [ Fig. 4(DeF) ].
The effects of WIN-55 on MMP-3 and -13 protein expression
In order to determine whether WIN-55 also inhibited MMP-3 and -13 expression at the protein level, pro and active MMP-3 and pro MMP-13 were measured in culture media using ELISA. Culture media obtained from chondrocytes isolated from grade 3 cartilage which had been cultured in alginate beads were used, as these demonstrated clear gene expression effects. Following stimulation of chondrocytes with IL-1b there was a significant increase in MMP-3 (P < 0.0001) and -13 (P ¼ 0.046) protein release into the media (Table II) . Treatment of chondrocytes with WIN-55 in combination with IL-1b significantly reduced both MMP-3 (P ¼ 0.0007) and -13 (P ¼ 0.0005) protein compared to IL-1b treatment alone (Table II) . WIN-55 treatment alone significantly reduced MMP-3 protein release to below basal levels (P ¼ 0.04) and MMP-13 (P ¼ 0.38) protein levels remained at basal level (Table II) .
Cannabinoid receptor expression in OA chondrocytes
To identify the expression of cannabinoid receptors CB1, CB2, PPARa and PPARg in chondrocytes cultured in monolayer immunocytochemistry was used. Here we observed the expression of CB1, CB2, PPARa and g [ Fig. 5 ]. PPARa and g expression was localised to the cytoplasm and nucleus [ Fig. 5 ].
Discussion
Cartilage degradation is a pathological feature of both OA and RA 1 . The inflammatory cytokine IL-1 plays a key role in cartilage destruction and stimulates increased production of MMPs by chondrocytes, resulting in the breakdown of collagen and proteoglycan 33 . Here, we have shown that treatment of articular chondrocytes from human OA cartilage with cannabinoid WIN-55 reduces the gene and protein expression of MMP-3 and MMP-13 in the presence of IL-1b, suggesting that cannabinoids may have potential in terms of arthritis therapy. In addition we have shown that WIN-55 significantly reduces the gene expression of TIMP-1 and TIMP-2 to below basal levels.
In this study we have used both monolayer and a 3D culture system for culture of chondrocytes. Chondrocytes that have been isolated from articular cartilage dedifferentiate in monolayer culture changing their matrix synthesis, with a decrease in type II collagen and aggrecan, developing a fibroblast like phenotype and an increase in collagen type I 28e30 . Dedifferentiation can be Results are expressed as mean and 95% confidence interval; *P < 0.05, ***P < 0.001,compared to DMSO vehicle control and þþþP < 0.001 compared to IL1b treatment alone.
reversed with the key phenotypic features of chondrocytes being preserved when cultured in a 3D system such as alginate beads 34 . In this study, chondrocytes were treated with IL-1b to mimic inflammatory processes in an in vitro model of OA .
In another study nonpsychoactive cannabinoid ajulemic acid (AJA) reduced MMP-1, MMP-3 and MMP-9 release from fibroblast like synovial cells stimulated with IL-1a and TNFa 8 . In vivo, AJA has also been shown to reduce the severity of adjuvant-induced arthritis 4 and other nonpsychoactive cannabinoids, cannabidiol (CBD) and HU-320 reduced inflammation and joint damage in murine collagen-induced arthritis 3, 5 . The effects of WIN-55 on articular chondrocytes did not appear to be influenced by the grade of the cartilage they were isolated from when cultured in monolayer. Chondrocytes cultured in monolayer express MMP-3 and MMP-13 at very low levels following WIN-55 treatment. However when comparing the effects of WIN-55 in monolayer to alginate bead culture, a greater inhibitory effect on MMP-3 and MMP-13 gene expression was seen in alginate bead cultured chondrocytes. Interestingly a biphasic expression pattern of MMP-3 and MMP-13 in response to WIN-55 was observed. MMP-3 was expressed in grade 0 and grade 3 cartilage derived chondrocytes and abolished in grade 2 cartilage . The biological activities of cannabinoids and the signal transduction pathways they induce or inhibit need to be further investigated in OA. Since TIMP-1 and -2 are decreased by WIN-55 in human OA chondrocytes it is unclear whether there is a change in MMP and TIMP balance following cannabinoid treatment. However the inhibitory effect of WIN-55 on MMP-3 and -13 expression would indicate a possible role of cannabinoids in suppressing IL-1b induced ECM degradation by MMPs.
We have observed the expression of both classical cannabinoid receptors CB1 and CB2 in human chondrocytes from OA cartilage at passage 2. CB1 and CB2 have previously been shown to be expressed at similar levels both at the protein and RNA level in synovia of patients with OA and RA and their expression is thought to play a role in the pathology of joint disease 52 . PPARa and g were also expressed in OA chondrocytes at passage 2 and their expression appears to be both cytoplasmic and nuclear. PPARs are nuclear receptors however studies have also shown that the localisation of PPARa receptors in chondrocytes is also cytoplasmic 53 . WIN-55
activates CB1 and CB2 with Kis of 1.89e123 nM and 0.28e 16.2 nM respectively 24 . In addition, WIN-55 has also been shown to activate PPARa and g 25, 26 . Targeting PPARs using both specific and cannabinoid agonists for the treatment of OA and RA has been reported previously 8,26,36,50,54e56 . The observed effects of WIN-55 on MMP and TIMP expression may be mediated by one or more of these receptors or by receptors as yet unknown.
In conclusion, in human OA chondrocytes, the synthetic cannabinoid WIN-55 inhibits the expression of matrix degrading enzymes MMP-3 and -13 and their inhibitors TIMP-1 and -2 in the presence or absence of IL-1b. This suggests a possible mechanism by which cannabinoids may act to prevent ECM breakdown in arthritis. Cannabinoids could provide a dual role in the treatment of arthritis as disease modifying agents in addition to having antiinflammatory properties 10 . Although there is increasing evidence to suggest that cannabinoids may be of therapeutic value in the treatment of arthritis, further studies into the receptors and signalling pathways involved in the actions of cannabinoids need to be investigated in order to elucidate their effects on catabolic and anabolic mediators in both normal and arthritic cartilage.
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